Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11709513 | 0.78 | CYP2C9 (0.36) | SIGMAR1CYP2C9 | |
| SCHEMBL75442 | 0.74 | SIGMAR1 (0.33) | SIGMAR1CYP2C9 | |
| SCHEMBL8189796 | 0.65 | HSD11B1 (0.37) | CYP2C9 | |
| SCHEMBL9408941 | 0.64 | APLNR (0.39) | APLNRSIGMAR1CYP2C9 | |
| SCHEMBL2932560 | 0.64 | APLNR (0.39) | APLNRSIGMAR1CYP2C9 | |
| SCHEMBL9408942 | 0.64 | APLNR (0.39) | APLNRSIGMAR1CYP2C9 | |
| SCHEMBL2932564 | 0.64 | APLNR (0.39) | APLNRSIGMAR1CYP2C9 | |
| SCHEMBL1538266 | 0.64 | APLNR (0.39) | APLNRSIGMAR1CYP2C9 | |
| SCHEMBL943424 | 0.64 | APLNR (0.39) | APLNRSIGMAR1CYP2C9 | |
| SCHEMBL13569826 | 0.63 | CYP2C9 (0.38) | SIGMAR1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109963885-B | Guanidine diphosphate and guanidine polyphosphate ligands and group IV metal catalysts produced therefrom | 陶氏环球技术有限责任公司 | 2022-06-14 | — | — | CN | disclosed |
| US-11066495-B2 | Phosphaguanidine group IV metal olefin polymerization catalysts | DOW GLOBAL TECHNOLOGY LLC (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3436429-B1 | BISCARBODIIMIDES AND POLYCARBODIIMIDES AND METHOD FOR THEIR PREPARATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-06-16 | — | — | EP | disclosed |
| US-11028190-B2 | Bis-phosphaguanidine and poly-phosphaguanidine ligands with group IV metal catalysts produced therefrom | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3519467-B1 | BIS-PHOSPHAGUANIDINE AND POLY-PHOSPHAGUANIDINE LIGANDS WITH GROUP IV METAL CATALYSTS PRODUCED THEREFROM | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3519470-B1 | PHOSPHAGUANIDINE GROUP IV METAL OLEFIN POLYMERIZATION CATALYSTS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200031960-A1 | PHOSPHAGUANIDINE GROUP IV METAL OLEFIN POLYMERIZATION CATALYSTS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-20190345271-A1 | BIS-PHOSPHAGUANIDINE AND POLY-PHOSPHAGUANIDINE LIGANDS WITH GROUP IV METAL CATALYSTS PRODUCED THEREFROM | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-11-14 | — | — | US | disclosed |
| EP-3519470-A1 | PHOSPHAGUANIDINE GROUP IV METAL OLEFIN POLYMERIZATION CATALYSTS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3519467-A1 | BIS-PHOSPHAGUANIDINE AND POLY-PHOSPHAGUANIDINE LIGANDS WITH GROUP IV METAL CATALYSTS PRODUCED THEREFROM | Dow Global Technologies LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20140256816-A1 | Adamantyl Derivatives as Therapeutic Agents | WOMEN & INFANTS' HOSPITAL OF RHODE ISLAND (US) | 2014-09-11 | — | — | US | disclosed |
| US-8772335-B2 | Adamantyl derivatives as therapeutic agents | WOMAN & INFANTS' HOSPITAL OF RHODE ISLAND (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130143962-A1 | Adamantyl Derivatives as Therapeutic Agents | WOMEN & INFANTS' HOSPITAL OF RHODE ISLAND (US) | 2013-06-06 | — | — | US | disclosed |
| EP-0986384-B1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-0986384-A4 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |
| US-6228794-B1 | EFFECTIVELY CATALYZE POLYMERIZATION OF OLEFINS IN ABSENCE OF ANY TRANSITION METAL | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2001-05-08 | — | — | US | disclosed |
| US-6071935-A | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors | PFIZER INC. (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0986384-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998050029-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066495-B2 | Phosphaguanidine group IV metal olefin polymerization catalysts | POLG, ODC1, RNGTT | APLNR 3455/4885SIGMAR1 1092/4885CYP2C9 2201/4885 |
| US-20130143962-A1 | Adamantyl Derivatives as Therapeutic Agents | MCL1, TOP2A, TP53 | APLNR 1736/4885SIGMAR1 3132/4885CYP2C9 3840/4885 |
| US-20140256816-A1 | Adamantyl Derivatives as Therapeutic Agents | MCL1, TOP2A, TP53 | APLNR 1736/4885SIGMAR1 3132/4885CYP2C9 3840/4885 |
| US-20200031960-A1 | PHOSPHAGUANIDINE GROUP IV METAL OLEFIN POLYMERIZATION CATALYSTS | POLG, ODC1, RNGTT | APLNR 3455/4885SIGMAR1 1092/4885CYP2C9 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.